Nanobiotix S.A. (EPA: NANO)

Market Cap	169.61M
Revenue (ttm)	42.20M
Net Income (ttm)	-33.47M
Shares Out	47.40M
EPS (ttm)	-0.78
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	13,593
Open	3.626
Previous Close	3.600
Day's Range	3.590 - 3.726
52-Week Range	3.528 - 7.930
Beta	1.29
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 13, 2024

About Nanobiotix

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2003
• Employees: 102
• Stock Exchange: Euronext Paris
• Ticker Symbol: NANO

Financial Performance

In 2023, Nanobiotix's revenue was 36.21 million, an increase of 658.12% compared to the previous year's 4.78 million. Losses were -39.70 million, -30.40% less than in 2022.